Bruce E Sands

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/364883/publications.pdf

Version: 2024-02-01

370 papers	44,688 citations	4653 85 h-index	2076 204 g-index
431 all docs	431 docs citations	431 times ranked	24053 citing authors

#	Article	IF	Citations
1	Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis. New England Journal of Medicine, 2005, 353, 2462-2476.	13.9	3,500
2	Infliximab for the Treatment of Fistulas in Patients with Crohn's Disease. New England Journal of Medicine, 1999, 340, 1398-1405.	13.9	2,665
3	Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment. Genome Biology, 2012, 13, R79.	13.9	2,258
4	Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis. New England Journal of Medicine, 2013, 369, 699-710.	13.9	2,114
5	Infliximab Maintenance Therapy for Fistulizing Crohn's Disease. New England Journal of Medicine, 2004, 350, 876-885.	13.9	2,026
6	Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease. New England Journal of Medicine, 2013, 369, 711-721.	13.9	2,001
7	Ustekinumab as Induction and Maintenance Therapy for Crohnâ€™s Disease. New England Journal of Medicine, 2016, 375, 1946-1960.	13.9	1,316
8	Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial. Gut, 2012, 61, 1693-1700.	6.1	1,295
9	Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis. New England Journal of Medicine, 2017, 376, 1723-1736.	13.9	1,232
10	STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD. Gastroenterology, 2021, 160, 1570-1583.	0.6	1,054
11	Ustekinumab Induction and Maintenance Therapy in Refractory Crohn's Disease. New England Journal of Medicine, 2012, 367, 1519-1528.	13.9	984
12	ACG Clinical Guideline: Management of Crohn's Disease in Adults. American Journal of Gastroenterology, 2018, 113, 481-517.	0.2	851
13	Early Mucosal Healing With Infliximab Is Associated With Improved Long-term Clinical Outcomes in Ulcerative Colitis. Gastroenterology, 2011, 141, 1194-1201.	0.6	792
14	Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis. New England Journal of Medicine, 2019, 381, 1201-1214.	13.9	703
15	The safety of vedolizumab for ulcerative colitis and Crohn's disease. Gut, 2017, 66, 839-851.	6.1	630
16	Effects of Vedolizumab Induction Therapy for Patients With Crohnâ€™s Disease in Whom Tumor Necrosis Factor Antagonist Treatment Failed. Gastroenterology, 2014, 147, 618-627.e3.	0.6	607
17	Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohnâ€™s disease. Gastroenterology, 2005, 128, 862-869.	0.6	548
18	Development of the CrohnÊ¼s disease digestive damage score, the LÃ©mann score. Inflammatory Bowel Diseases, 2011, 17, 1415-1422.	0.9	496

#	Article	IF	Citations
19	Developing an instrument to assess the endoscopic severity of ulcerative colitis: the Ulcerative Colitis Endoscopic Index of Severity (UCEIS). Gut, 2012, 61, 535-542.	6.1	463
20	Risk of Lymphoma Associated With Combination Antiâ€“Tumor Necrosis Factor and Immunomodulator Therapy for the Treatment of Crohn's Disease: A Meta-Analysis. Clinical Gastroenterology and Hepatology, 2009, 7, 874-881.	2.4	459
21	Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis. New England Journal of Medicine, 2019, 381, 1215-1226.	13.9	457
22	Colectomy Rate Comparison After Treatment of Ulcerative Colitis With Placebo or Infliximab. Gastroenterology, 2009, 137, 1250-1260.	0.6	440
23	Infliximab in the Treatment of Severe, Steroid-Refractory Ulcerative Colitis: A Pilot Study. Inflammatory Bowel Diseases, 2001, 7, 83-88.	0.9	377
24	The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD With the European Crohn's and Colitis Organization: When to Start, When to Stop, Which Drug to Choose, and How to Predict Response?. American Journal of Gastroenterology, 2011, 106, 199-212.	0.2	356
25	Reliability and Initial Validation of the Ulcerative Colitis Endoscopic Index of Severity. Gastroenterology, 2013, 145, 987-995.	0.6	354
26	LRRK2 Is Involved in the IFN-Î³ Response and Host Response to Pathogens. Journal of Immunology, 2010, 185, 5577-5585.	0.4	350
27	Microbiotas from Humans with Inflammatory Bowel Disease Alter the Balance of Gut Th17 and RORÎ³t+ Regulatory T Cells and Exacerbate Colitis in Mice. Immunity, 2019, 50, 212-224.e4.	6.6	345
28	Long-term treatment of rectovaginal fistulas in Crohnâ€™s disease: Response to infliximab in the ACCENT II Study. Clinical Gastroenterology and Hepatology, 2004, 2, 912-920.	2.4	327
29	From symptom to diagnosis: clinical distinctions among various forms of intestinal inflammation. Gastroenterology, 2004, 126, 1518-1532.	0.6	311
30	Biomarkers of Inflammation in Inflammatory Bowel Disease. Gastroenterology, 2015, 149, 1275-1285.e2.	0.6	287
31	Tofacitinib for induction and maintenance therapy of Crohn's disease: results of two phase IIb randomised placebo-controlled trials. Gut, 2017, 66, 1049-1059.	6.1	274
32	Impact of Hospital Volume on Postoperative Morbidity and Mortality Following a Colectomy for Ulcerative Colitis. Gastroenterology, 2008, 134, 680-687.e1.	0.6	264
33	Systematic review with metaâ€analysis: mucosal healing is associated with improved longâ€term outcomes in Crohn's disease. Alimentary Pharmacology and Therapeutics, 2016, 43, 317-333.	1.9	264
34	The Real-World Effectiveness and Safety of Vedolizumab for Moderateâ€“Severe Crohnâ€™s Disease: Results From the US VICTORY Consortium. American Journal of Gastroenterology, 2016, 111, 1147-1155.	0.2	257
35	Mucosal Healing Is Associated With Improved Long-term Outcomes of Patients With Ulcerative Colitis: A Systematic Review and Meta-analysis. Clinical Gastroenterology and Hepatology, 2016, 14, 1245-1255.e8.	2.4	255
36	Inflammatory bowel disease: past, present, and future. Journal of Gastroenterology, 2007, 42, 16-25.	2.3	238

#	Article	IF	Citations
37	Efficacy and Safety of MEDI2070, an Antibody Against Interleukin 23, in Patients With Moderate to Severe Crohnâ€™s Disease: A Phase 2a Study. Gastroenterology, 2017, 153, 77-86.e6.	0.6	232
38	Perioperative Treatment with Infliximab in Patients with Crohnâ€™s Disease and Ulcerative Colitis is Not Associated with an Increased Rate of Postoperative Complications. Journal of Gastrointestinal Surgery, 2008, 12, 1730-1737.	0.9	215
39	The Trefoil Peptide Family. Annual Review of Physiology, 1996, 58, 253-273.	5.6	208
40	Preliminary evaluation of safety and activity of recombinant human interleukin 11 in patients with active Crohn's disease. Gastroenterology, 1999, 117, 58-64.	0.6	200
41	Therapy of inflammatory bowel disease. Gastroenterology, 2000, 118, S68-S82.	0.6	200
42	Guidelines for Immunizations in Patients With Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2004, 10, 677-692.	0.9	200
43	Rosiglitazone for Active Ulcerative Colitis: A Randomized Placebo-Controlled Trial. Gastroenterology, 2008, 134, 688-695.	0.6	198
44	American Gastroenterological Association Consensus Development Conference on the Use of Biologics in the Treatment of Inflammatory Bowel Disease, June 21â€“23, 2006. Gastroenterology, 2007, 133, 312-339.	0.6	197
45	A Randomized, Double-Blind, Sham-Controlled Study of Granulocyte/Monocyte Apheresis for Active Ulcerative Colitis. Gastroenterology, 2008, 135, 400-409.	0.6	197
46	The Inflammatory Bowel Diseases and Ambient Air Pollution: A Novel Association. American Journal of Gastroenterology, 2010, 105, 2412-2419.	0.2	197
47	A Pooled Analysis of Infections, Malignancy, and Mortality in Infliximab- and Immunomodulator-Treated Adult Patients With Inflammatory Bowel Disease. American Journal of Gastroenterology, 2012, 107, 1051-1063.	0.2	194
48	Safety of Tofacitinib for Treatment of Ulcerative Colitis, Based on 4.4 Years of Data From Global Clinical Trials. Clinical Gastroenterology and Hepatology, 2019, 17, 1541-1550.	2.4	191
49	Fontolizumab in moderate to severe CrohnÊ¼s disease: A phase 2, randomized, double-blind, placebo-controlled, multiple-dose study. Inflammatory Bowel Diseases, 2010, 16, 233-242.	0.9	187
50	Converging Goals of Treatment of Inflammatory Bowel Disease From Clinical Trials and Practice. Gastroenterology, 2015, 148, 37-51.e1.	0.6	185
51	Long-term Infliximab Maintenance Therapy for Ulcerative Colitis: The ACT-1 and -2 Extension Studies. Inflammatory Bowel Diseases, 2012, 18, 201-211.	0.9	181
52	Crohnâ€™s Disease Patientsâ€™ Risk-Benefit Preferences: Serious Adverse Event Risks Versus Treatment Efficacy. Gastroenterology, 2007, 133, 769-779.	0.6	167
53	Sex-Based Differences in Incidence of Inflammatory Bowel Diseasesâ€”Pooled Analysis of Population-Based Studies From Western Countries. Gastroenterology, 2018, 155, 1079-1089.e3.	0.6	155
54	Acute and late toxicity of patients with inflammatory bowel disease undergoing irradiation for abdominal and pelvic neoplasms. International Journal of Radiation Oncology Biology Physics, 2000, 46, 995-998.	0.4	151

#	Article	IF	Citations
55	Functionally defective germline variants of sialic acid acetylesterase in autoimmunity. Nature, 2010, 466, 243-247.	13.7	150
56	IM-UNITI: Three-year Efficacy, Safety, and Immunogenicity of Ustekinumab Treatment of Crohnâ€™s Disease. Journal of Crohn's and Colitis, 2020, 14, 23-32.	0.6	149
57	The Role of TNFÎ± in Ulcerative Colitis. Journal of Clinical Pharmacology, 2007, 47, 930-941.	1.0	145
58	Pregnancy and Neonatal Outcomes After Fetal Exposure to Biologics and Thiopurines Among Women With Inflammatory Bowel Disease. Gastroenterology, 2021, 160, 1131-1139.	0.6	145
59	Vedolizumab as Induction and Maintenance Therapy for CrohnÊ¼s Disease in Patients NaÃ¯ve to or Who Have Failed Tumor Necrosis Factor Antagonist Therapy. Inflammatory Bowel Diseases, 2017, 23, 97-106.	0.9	143
60	Long-term Efficacy of Vedolizumab for Crohnâ€™s Disease. Journal of Crohn's and Colitis, 2017, 11, jjw176.	0.6	141
61	Long-term Efficacy of Vedolizumab for Ulcerative Colitis. Journal of Crohn's and Colitis, 2017, 11, jjw177.	0.6	140
62	Safety and tolerability of concurrent natalizumab treatment for patients with CrohnÊ¼s disease not in remission while receiving infliximab. Inflammatory Bowel Diseases, 2007, 13, 2-11.	0.9	138
63	Transition of Adolescents With Inflammatory Bowel Disease From Pediatric to Adult Care: A Survey of Adult Gastroenterologists. Journal of Pediatric Gastroenterology and Nutrition, 2009, 48, 61-65.	0.9	138
64	Venous thromboembolic events in the tofacitinib ulcerative colitis clinical development programme. Alimentary Pharmacology and Therapeutics, 2019, 50, 1068-1076.	1.9	132
65	Risks and Benefits of Infliximab for the Treatment of Crohnâ€™s Disease. Clinical Gastroenterology and Hepatology, 2006, 4, 1017-1024.	2.4	130
66	Exposureâ€“efficacy Relationships for Vedolizumab Induction Therapy in Patients with Ulcerative Colitis or Crohnâ€™s Disease. Journal of Crohn's and Colitis, 2017, 11, 921-929.	0.6	130
67	Longâ€term efficacy and safety of ustekinumab for Crohn's disease through the second year of therapy. Alimentary Pharmacology and Therapeutics, 2018, 48, 65-77.	1.9	128
68	Randomized, controlled trial of recombinant human interleukin-11 in patients with active Crohn's disease. Alimentary Pharmacology and Therapeutics, 2002, 16, 399-406.	1.9	127
69	Abatacept for Crohn's Disease and Ulcerative Colitis. Gastroenterology, 2012, 143, 62-69.e4.	0.6	127
70	Possible Association Between Isotretinoin and Inflammatory Bowel Disease. American Journal of Gastroenterology, 2006, 101, 1569-1573.	0.2	125
71	Risk of Early Surgery for Crohn's Disease: Implications for Early Treatment Strategies. American Journal of Gastroenterology, 2003, 98, 2712-2718.	0.2	124
72	Anti-Saccharomyces cerevisiae antibody (ASCA) positivity is associated with increased risk for early surgery in Crohn's disease. Gut, 2004, 53, 1117-1122.	6.1	122

#	Article	IF	Citations
73	The Risk of Developing Crohn's Disease After an Appendectomy: A Meta-Analysis. American Journal of Gastroenterology, 2008, 103, 2925-2931.	0.2	121
74	Open: Vedolizumab for Ulcerative Colitis: Treatment Outcomes from the VICTORY Consortium. American Journal of Gastroenterology, 2018, 113, 1345.	0.2	119
75	Outcome of Surgical Versus Percutaneous Drainage of Abdominal and Pelvic Abscesses in Crohn's Disease. American Journal of Gastroenterology, 2006, 101, 2283-2289.	0.2	118
76	Gut microbiota density influences host physiology and is shaped by host and microbial factors. ELife, 2019, 8, .	2.8	118
77	Fatigue is highly associated with poor healthâ€related quality of life, disability and depression in newlyâ€diagnosed patients with inflammatory bowel disease, independent of disease activity. Alimentary Pharmacology and Therapeutics, 2014, 39, 811-822.	1.9	116
78	Occurrence of Colon Ischemia in Relation to Irritable Bowel Syndrome. American Journal of Gastroenterology, 2004, 99, 486-491.	0.2	114
79	Development of an index to define overall disease severity in IBD. Gut, 2018, 67, 244-254.	6.1	108
80	Maintenance infliximab does not result in increased abscess development in fistulizing Crohn's disease: results from the ACCENT II study. Alimentary Pharmacology and Therapeutics, 2006, 23, 1127-1136.	1.9	107
81	Developing a Standard Set of Patient-Centred Outcomes for Inflammatory Bowel Diseaseâ€”an International, Cross-disciplinary Consensus. Journal of Crohn's and Colitis, 2018, 12, 408-418.	0.6	102
82	Serological response to the 2009 H1N1 influenza vaccination in patients with inflammatory bowel disease. Gut, 2012, 61, 385-391.	6.1	100
83	Repifermin (keratinocyte growth factor-2) for the treatment of active ulcerative colitis: a randomized, double-blind, placebo-controlled, dose-escalation trial. Alimentary Pharmacology and Therapeutics, 2003, 17, 1355-1364.	1.9	99
84	Intestinal Inflammation Modulates the Expression of ACE2 and TMPRSS2 and Potentially Overlaps With the Pathogenesis of SARS-CoV-2â€related Disease. Gastroenterology, 2021, 160, 287-301.e20.	0.6	98
85	Longâ€term safety of vedolizumab for inflammatory bowel disease. Alimentary Pharmacology and Therapeutics, 2020, 52, 1353-1365.	1.9	97
86	Risk Factors for Colon Ischemia. American Journal of Gastroenterology, 2004, 99, 1333-1337.	0.2	95
87	Peficitinib, an Oral Janus Kinase Inhibitor, in Moderate-to-severe Ulcerative Colitis: Results From a Randomised, Phase 2 Study. Journal of Crohn's and Colitis, 2018, 12, 1158-1169.	0.6	95
88	Five-Year Efficacy and Safety of Ustekinumab Treatment in Crohnâ€™s Disease: The IM-UNITI Trial. Clinical Gastroenterology and Hepatology, 2022, 20, 578-590.e4.	2.4	94
89	Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial. Lancet, The, 2022, 399, 2200-2211.	6.3	94
90	Development and Validation of a Scoring System to Predict Outcomes of Vedolizumab Treatment in Patients With Crohnâ€™sÂDisease. Gastroenterology, 2018, 155, 687-695.e10.	0.6	93

#	Article	IF	Citations
91	Guselkumab for the Treatment of Crohnâ€™s Disease: Induction Results From the Phase 2 GALAXI-1 Study. Gastroenterology, 2022, 162, 1650-1664.e8.	0.6	88
92	Randomized, double-blind, placebo-controlled trial of the oral interleukin-12/23 inhibitor apilimod mesylate for treatment of active CrohnÊ¼s disease. Inflammatory Bowel Diseases, 2010, 16, 1209-1218.	0.9	82
93	Tofacitinib in Patients with Ulcerative Colitis: Health-Related Quality of Life in Phase 3 Randomised Controlled Induction and Maintenance Studies. Journal of Crohn's and Colitis, 2018, 12, 145-156.	0.6	80
94	Tofacitinib Treatment Is Associated With Modest and Reversible Increases in Serum Lipids in Patients With Ulcerative Colitis. Clinical Gastroenterology and Hepatology, 2020, 18, 123-132.e3.	2.4	79
95	State of the Art: Ibd Therapy and Clinical Trials in Ibd. Inflammatory Bowel Diseases, 2005, 11, S3-S12.	0.9	77
96	Prevention and treatment of osteoporosis in inflammatory bowel disease. Inflammatory Bowel Diseases, 2006, 12, 797-813.	0.9	75
97	A Survey of Current Practice of Venous Thromboembolism Prophylaxis in Hospitalized Inflammatory Bowel Disease Patients in the United States. Journal of Clinical Gastroenterology, 2013, 47, e1-e6.	1.1	73
98	Real-time tool to display the predicted disease course and treatment response for children with CrohnÊ¼s disease. Inflammatory Bowel Diseases, 2011, 17, 30-38.	0.9	72
99	Ulcerative colitis is characterized by a plasmablast-skewed humoral response associated with disease activity. Nature Medicine, 2022, 28, 766-779.	15.2	70
100	Anti-TNFÎ± Therapies Are Safe During Pregnancy in Women with Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2014, 20, 1862-1869.	0.9	69
101	The risk of developing Crohn's disease after an appendectomy: a population-based cohort study in Sweden and Denmark. Gut, 2007, 56, 1387-1392.	6.1	68
102	Presenting symptoms in inflammatory bowel disease: descriptive analysis of a community-based inception cohort. BMC Gastroenterology, 2019, 19, 47.	0.8	68
103	Selecting End Points for Disease-Modification Trials in Inflammatory Bowel Disease: the SPIRIT Consensus From the IOIBD. Gastroenterology, 2021, 160, 1452-1460.e21.	0.6	68
104	Methotrexate Is Not Superior to Placebo in Maintaining Steroid-Free Response or Remission in Ulcerative Colitis. Gastroenterology, 2018, 155, 1098-1108.e9.	0.6	67
105	Safety of Ustekinumab in Inflammatory Bowel Disease: Pooled Safety Analysis of Results from Phase 2/3 Studies. Inflammatory Bowel Diseases, 2021, 27, 994-1007.	0.9	66
106	Efficacy and safety of tofacitinib dose deâ€escalation and dose escalation for patients with ulcerative colitis: results from OCTAVE Open. Alimentary Pharmacology and Therapeutics, 2020, 51, 271-280.	1.9	65
107	Patient perceptions of the risks and benefits of infliximab for the treatment of inflammatory bowel disease. Inflammatory Bowel Diseases, 2008, 14, 1-6.	0.9	61
108	Are Gastroenterologists Less Tolerant of Treatment Risks than Patients? Benefit-Risk Preferences in Crohn's Disease Management. Journal of Managed Care Pharmacy, 2010, 16, 616-628.	2.2	61

#	Article	IF	Citations
109	Eldelumab [Anti-IP-10] Induction Therapy for Ulcerative Colitis: A Randomised, Placebo-Controlled, Phase 2b Study. Journal of Crohn's and Colitis, 2016, 10, 418-428.	0.6	60
110	Retrospective Analysis of Safety of Vedolizumab in Patients With Inflammatory Bowel Diseases. Clinical Gastroenterology and Hepatology, 2019, 17, 1533-1540.e2.	2.4	60
111	Ustekinumab Pharmacokinetics and Exposure Response in a Phase 3 Randomized Trial of Patients With Ulcerative Colitis. Clinical Gastroenterology and Hepatology, 2020, 18, 2244-2255.e9.	2.4	60
112	Efficacy and Safety of Mirikizumab in a Randomized Phase 2 Study of Patients With Crohnâ€™s Disease. Gastroenterology, 2022, 162, 495-508.	0.6	60
113	Effects of Mongersen (GED-0301) on Endoscopic and Clinical Outcomes in Patients With Active Crohnâ€™s Disease. Gastroenterology, 2018, 154, 61-64.e6.	0.6	59
114	Impact of the Mobile HealthPROMISE Platform on the Quality of Care and Quality of Life in Patients With Inflammatory Bowel Disease: Study Protocol of a Pragmatic Randomized Controlled Trial. JMIR Research Protocols, 2015, 4, e23.	0.5	58
115	An increased risk of Crohn's disease in individuals who inherit the HLA class II DRB3*0301 allele.. Proceedings of the National Academy of Sciences of the United States of America, 1996, 93, 5094-5098.	3.3	57
116	An International Consensus to Standardize Integration of Histopathology in Ulcerative Colitis Clinical Trials. Gastroenterology, 2021, 160, 2291-2302.	0.6	57
117	Mongersen (GED-0301) for Active Crohn's Disease: Results of a Phase 3 Study. American Journal of Gastroenterology, 2020, 115, 738-745.	0.2	56
118	Human Placenta-derived Cells (PDA-001) for the Treatment of Moderate-to-severe CrohnÊ¼s Disease. Inflammatory Bowel Diseases, 2015, 21, 1809-1816.	0.9	54
119	Incidence of Colonic Ischemia, Hospitalized Complications of Constipation, and Bowel Surgery in Relation To Use of Alosetron Hydrochloride. American Journal of Gastroenterology, 2003, 98, 1117-1122.	0.2	53
120	Fistula Healing in Pivotal Studies of Ustekinumab in Crohn's Disease. Gastroenterology, 2017, 152, S185.	0.6	53
121	Immunoglobulin A Targets a Unique Subset of the Microbiota in Inflammatory Bowel Disease. Cell Host and Microbe, 2021, 29, 83-93.e3.	5.1	53
122	New Therapeutics for Ulcerative Colitis. Annual Review of Medicine, 2021, 72, 199-213.	5.0	52
123	When should ulcerative colitis patients undergo colectomy for dysplasia? Mismatch between patient preferences and physician recommendations. Inflammatory Bowel Diseases, 2010, 16, 1658-1662.	0.9	51
124	A randomised, double-blind, sham-controlled study of granulocyte/monocyte apheresis for moderate to severe Crohn's disease. Gut, 2013, 62, 1288-1294.	6.1	51
125	A Frameshift in CSF2RB Predominant Among Ashkenazi Jews Increases Risk for Crohn's Disease and Reduces Monocyte Signaling via GM-CSF. Gastroenterology, 2016, 151, 710-723.e2.	0.6	51
126	The Impact of Clinical Information on the Assessment of Endoscopic Activity: Characteristics of the Ulcerative Colitis Endoscopic Index Of Severity [UCEIS]. Journal of Crohn's and Colitis, 2015, 9, 607-616.	0.6	50

#	Article	IF	Citations
127	Predictors and Management of Loss of Response to Vedolizumab in Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2018, 24, 2461-2467.	0.9	50
128	The SCENIC Consensus Statement on Surveillance and Management of Dysplasia in Inflammatory Bowel Disease: Praise and Words of Caution. Gastroenterology, 2015, 148, 462-467.	0.6	48
129	Approaches to Integrating Biomarkers Into Clinical Trials and Care Pathways as Targets for the Treatment of Inflammatory Bowel Diseases. Gastroenterology, 2019, 157, 1032-1043.e1.	0.6	48
130	Comparative safety and effectiveness of vedolizumab to tumour necrosis factor antagonist therapy for Crohn's disease. Alimentary Pharmacology and Therapeutics, 2020, 52, 669-681.	1.9	48
131	Relationship Between Combined Histologic and Endoscopic Endpoints and Efficacy of Ustekinumab Treatment in Patients With Ulcerative Colitis. Gastroenterology, 2020, 159, 2052-2064.	0.6	48
132	Development and Validation of Clinical Scoring Tool to Predict Outcomes of Treatment With Vedolizumab in Patients With Ulcerative Colitis. Clinical Gastroenterology and Hepatology, 2020, 18, 2952-2961.e8.	2.4	48
133	Variation in Treatment of Patients With Inflammatory Bowel Diseases at Major Referral Centers in the United States. Clinical Gastroenterology and Hepatology, 2015, 13, 1197-1200.	2.4	47
134	Efficacy and Safety of Maintenance Ustekinumab for Ulcerative Colitis Through 3 Years: UNIFI Long-term Extension. Journal of Crohn's and Colitis, 2022, 16, 1222-1234.	0.6	47
135	Treatment with a Broad-Spectrum Cephalosporin versus Piperacillin-Tazobactam and the Risk for Isolation of Broad-Spectrum Cephalosporin-Resistant Enterobacter Species. Antimicrobial Agents and Chemotherapy, 2003, 47, 1882-1886.	1.4	46
136	Risk factors for colorectal cancer in CrohnÊ¼s colitis: A case-control study. Inflammatory Bowel Diseases, 2006, 12, 491-496.	0.9	46
137	SMAD3 gene variant is a risk factor for recurrent surgery in patients with Crohn's disease. Journal of Crohn's and Colitis, 2014, 8, 845-851.	0.6	46
138	High-Dose Infliximab Therapy in Crohnâ€™s Disease: Clinical Experience, Safety, and Efficacy. Journal of Crohn's and Colitis, 2015, 9, 266-275.	0.6	46
139	Adverse Events Do Not Outweigh Benefits of Combination Therapy for Crohn's Disease in a Decision Analytic Model. Clinical Gastroenterology and Hepatology, 2012, 10, 46-51.	2.4	45
140	Ciprofloxacin for the Prevention of Postoperative Recurrence in Patients with CrohnÊ¼s Disease. Inflammatory Bowel Diseases, 2013, 19, 1073-1079.	0.9	45
141	Immediate versus tailored prophylaxis to prevent symptomatic recurrences after surgery for ileocecal Crohn's disease?. Surgery, 2011, 149, 72-78.	1.0	44
142	Shorter Disease Duration Is Associated With Higher Rates of Response to Vedolizumab in Patients With Crohnâ€™s Disease But Not Ulcerative Colitis. Clinical Gastroenterology and Hepatology, 2019, 17, 2497-2505.e1.	2.4	44
143	O-001â€ƒA Multicenter, Double-Blind, Placebo-Controlled Phase3 Study of Ustekinumab, a Human IL-12/23P40 mAB, in Moderate-Service CrohnÊ¼s Disease Refractory to Anti-TFNÎ±. Inflammatory Bowel Diseases, 2016, 22, S1.	0.9	42
144	Long-term Safety and Efficacy of Etrasimod for Ulcerative Colitis: Results from the Open-label Extension of the OASIS Study. Journal of Crohn's and Colitis, 2021, 15, 950-959.	0.6	42

#	Article	IF	Citations
145	A Survey of Methodological Variation in the CrohnÊ¼s Disease Activity Index. Inflammatory Bowel Diseases, 2005, 11, 133-138.	0.9	41
146	Biologic therapy for inflammatory bowel disease. Inflammatory Bowel Diseases, 1997, 3, 95-113.	0.9	40
147	Review article: medical therapy for fistulizing Crohn's disease. Alimentary Pharmacology and Therapeutics, 2006, 24, 1283-1293.	1.9	40
148	Ustekinumab is effective and safe for ulcerative colitis through 2 years of maintenance therapy. Alimentary Pharmacology and Therapeutics, 2020, 52, 1658-1675.	1.9	40
149	Analysis of MHC class II DP, DQ and DR alleles in Crohnâ€™s disease. Gut, 1998, 43, 210-215.	6.1	39
150	Biologic Therapy for Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 1997, 3, 95-113.	0.9	38
151	Are Adult Patients More Tolerant of Treatment Risks Than Parents of Juvenile Patients?. Risk Analysis, 2009, 29, 121-136.	1.5	38
152	Characterization of patients with infliximab-induced lupus erythematosus and outcomes after retreatment with a second anti-TNF agent. Inflammatory Bowel Diseases, 2011, 17, 99-104.	0.9	38
153	Basiliximab Does Not Increase Efficacy of Corticosteroids in Patients With Steroid-Refractory Ulcerative Colitis. Gastroenterology, 2012, 143, 356-364.e1.	0.6	38
154	Rates of pharmacologic venous thromboembolism prophylaxis in hospitalized patients with active ulcerative colitis: Results from a tertiary care center. Journal of Crohn's and Colitis, 2013, 7, e635-e640.	0.6	38
155	Microbial Engraftment and Efficacy of Fecal Microbiota Transplant for Clostridium Difficile in Patients With and Without Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2019, 25, 969-979.	0.9	38
156	Design Issues and Outcomes in Ibd Clinical Trials. Inflammatory Bowel Diseases, 2005, 11, S22-S28.	0.9	37
157	Efficacy and Safety of Extended Induction With Tofacitinib for the Treatment of Ulcerative Colitis. Clinical Gastroenterology and Hepatology, 2022, 20, 1821-1830.e3.	2.4	37
158	New life in a sleeper: Thalidomide and Crohn's disease. Gastroenterology, 1999, 117, 1485-1488.	0.6	36
159	Immunosuppressive drugs in ulcerative colitis: twisting facts to suit theories?. Gut, 2006, 55, 437-441.	6.1	36
160	Efficacy and Safety of Tofacitinib in Ulcerative Colitis Based on Prior Tumor Necrosis Factor Inhibitor Failure Status. Clinical Gastroenterology and Hepatology, 2022, 20, 591-601.e8.	2.4	36
161	Defining the Optimal Response Criteria for the Crohn's Disease Activity Index for Induction Studies in Patients With Mildly to Moderately Active Crohn's Disease. American Journal of Gastroenterology, 2008, 103, 3123-3131.	0.2	35
162	Can endoscopy be avoided in the assessment of ulcerative colitis in clinical trials?. Inflammatory Bowel Diseases, 2012, 18, 2056-2062.	0.9	34

#	Article	IF	Citations
163	437 Do Infant Serum Levels of Biologic Agents at Birth Correlate With Risk of Adverse Outcomes? Results From the PIANO Registry. Gastroenterology, 2016, 150, S91-S92.	0.6	34
164	Predictors of Hospital Readmissions for Ulcerative Colitis in the United States. Inflammatory Bowel Diseases, 2017, 23, 1.	0.9	34
165	Accelerated Infliximab Dosing Increases 30-Day Colectomy in Hospitalized Ulcerative Colitis Patients: A Propensity Score Analysis. Inflammatory Bowel Diseases, 2018, 24, 651-659.	0.9	34
166	Identification of Endpoints for Development of Antifibrosis Drugs for Treatment of Crohnâ€™s Disease. Gastroenterology, 2018, 155, 76-87.	0.6	34
167	Molecular Cloning of the Rat Intestinal Trefoil Factor Gene. Journal of Biological Chemistry, 1995, 270, 9353-9361.	1.6	33
168	Challenges in Designing a National Surveillance Program for Inflammatory Bowel Disease in the United States. Inflammatory Bowel Diseases, 2014, 20, 398-415.	0.9	33
169	Assessing Colonic Exposure, Safety, and Clinical Activity of SRT2104, a Novel Oral SIRT1 Activator, in Patients with Mild to Moderate Ulcerative Colitis. Inflammatory Bowel Diseases, 2016, 22, 607-614.	0.9	33
170	Pilot Feasibility Studies of Leukocytapheresis With the Adacolumn Apheresis System in Patients With Active Ulcerative Colitis or Crohn Disease. Journal of Clinical Gastroenterology, 2006, 40, 482-489.	1.1	32
171	Comparative Safety and Effectiveness of Vedolizumab to Tumor Necrosis Factor Antagonist Therapy for Ulcerative Colitis. Clinical Gastroenterology and Hepatology, 2022, 20, 126-135.	2.4	32
172	Prospective Cohort Study to Investigate the Safety of Preoperative Tumor Necrosis Factor Inhibitor Exposure in Patients With Inflammatory Bowel Disease Undergoing Intra-abdominal Surgery. Gastroenterology, 2022, 163, 204-221.	0.6	32
173	Eldelumab [anti-interferon-Î³-inducible protein-10 antibody] Induction Therapy for Active Crohnâ€™s Disease: a Randomised, Double-blind, Placebo-controlled Phase IIa Study. Journal of Crohn's and Colitis, 2017, 11, 811-819.	0.6	31
174	NOVEL THERAPIES FOR INFLAMMATORY BOWEL DISEASE. Gastroenterology Clinics of North America, 1999, 28, 323-351.	1.0	30
175	Effects of Growth Hormone Secretion on Body Composition in Patients with Crohnâ€™s Disease. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 5468-5472.	1.8	30
176	Body Image Dissatisfaction in Patients with Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2015, 21, 345-352.	0.9	30
177	A clinical decision support tool may help to optimise vedolizumab therapy in Crohnâ€™s disease. Alimentary Pharmacology and Therapeutics, 2020, 51, 553-564.	1.9	30
178	Adverse events of special interest in clinical trials of rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and psoriasis with 37â€‰066 patient-years of tofacitinib exposure. RMD Open, 2021, 7, e001595.	1.8	30
179	Algorithms to identify colonic ischemia, complications of constipation and irritable bowel syndrome in medical claims data: development and validation. Pharmacoepidemiology and Drug Safety, 2006, 15, 47-56.	0.9	29
180	Efficacy of methotrexate in ulcerative colitis. Inflammatory Bowel Diseases, 2010, 16, 1421-1430.	0.9	29

#	Article	IF	Citations
181	Selective Leukocyte Apheresis for the Treatment of Inflammatory Bowel Disease. Journal of Clinical Gastroenterology, 2007, 41, 874-888.	1.1	28
182	Menstrual Cycle Changes in Women with Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2014, 20, 534-540.	0.9	28
183	Serum Proteome Profiles in Stricturing CrohnÊ¼s Disease. Inflammatory Bowel Diseases, 2015, 21, 1935-1941.	0.9	28
184	Early readmission in patients hospitalized for ulcerative colitis: incidence and risk factors. Scandinavian Journal of Gastroenterology, 2015, 50, 1103-1109.	0.6	28
185	Fecal Calprotectin Responses Following Induction Therapy With Vedolizumab in Moderate to Severe Ulcerative Colitis: A Post Hoc Analysis of GEMINI 1. Inflammatory Bowel Diseases, 2019, 25, 803-810.	0.9	28
186	Risk of Extraintestinal Solid Cancer with Anti-TNF Therapy in Adults with Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2013, 19, 644-649.	0.9	27
187	Anastomotic Ulcers After Ileocolic Resection for Crohnâ€™s Disease Are Common and Predict Recurrence. Inflammatory Bowel Diseases, 2020, 26, 1050-1058.	0.9	27
188	Comparison of the EMA and FDA Guidelines on Ulcerative Colitis Drug Development. Clinical Gastroenterology and Hepatology, 2019, 17, 1673-1679.e1.	2.4	26
189	Integrative Analysis of the Inflammatory Bowel Disease Serum Metabolome Improves Our Understanding of Genetic Etiology and Points to Novel Putative Therapeutic Targets. Gastroenterology, 2022, 162, 828-843.e11.	0.6	26
190	The Placebo Response Rate in Irritable Bowel Syndrome and Inflammatory Bowel Disease. Digestive Diseases, 2009, 27, 68-75.	0.8	24
191	Colorectal cancer in Crohnâ€™s colitis is comparable to sporadic colorectal cancer. International Journal of Colorectal Disease, 2016, 31, 973-982.	1.0	23
192	Machine learning identifies novel blood protein predictors of penetrating and stricturing complications in newly diagnosed paediatric Crohn's disease. Alimentary Pharmacology and Therapeutics, 2021, 53, 281-290.	1.9	23
193	Investigator-Initiated IBD Trials in the United States. Inflammatory Bowel Diseases, 2017, 23, 14-22.	0.9	22
194	Longitudinal Autonomic Nervous System Measures Correlate With Stress and Ulcerative Colitis Disease Activity and Predict Flare. Inflammatory Bowel Diseases, 2021, 27, 1576-1584.	0.9	22
195	The Risks and Benefits of Early Immunosuppression and Biological Therapy. Digestive Diseases, 2012, 30, 100-106.	0.8	21
196	Incidence of CrohnÊ¼s Disease and Ulcerative Colitis in Rhode Island. Inflammatory Bowel Diseases, 2016, 22, 1456-1461.	0.9	21
197	A Longitudinal Study of Sexual Function in Women With Newly Diagnosed Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2019, 25, 1262-1270.	0.9	21
198	OP34 VARSITY: A double-blind, double-dummy, randomised, controlled trial of vedolizumab versus adalimumab in patients with active ulcerative colitis. Journal of Crohn's and Colitis, 2019, 13, S612-S613.	0.6	21

#	Article	IF	Citations
199	Histologic Outcomes With Vedolizumab Versus Adalimumab in Ulcerative Colitis: Results From An Efficacy and Safety Study of Vedolizumab Intravenous Compared to Adalimumab Subcutaneous in Participants With Ulcerative Colitis (VARSITY). Gastroenterology, 2021, 161, 1156-1167.e3.	0.6	21
200	Validation of interactive voice response system administration of the short inflammatory bowel disease questionnaire. Inflammatory Bowel Diseases, 2009, 15, 599-607.	0.9	20
201	High Prevalence of Malnutrition and Micronutrient Deficiencies in Patients With Inflammatory Bowel Disease Early in Disease Course. Inflammatory Bowel Diseases, 2023, 29, 423-429.	0.9	20
202	Leukocyte Anti-Trafficking Strategies: Current Status and Future Directions. Digestive Diseases, 2017, 35, 13-20.	0.8	18
203	There is Significant Practice Pattern Variability in the Management of the Hospitalized Ulcerative Colitis Patient at a Tertiary Care and IBD Referral Center. Journal of Clinical Gastroenterology, 2018, 52, 333-338.	1.1	18
204	The Role of Resilience in Irritable Bowel Syndrome, Other Chronic Gastrointestinal Conditions, and the General Population. Clinical Gastroenterology and Hepatology, 2020, 19, 2541-2550.e1.	2.4	18
205	Endpoints for extraintestinal manifestations in inflammatory bowel disease trials: the EXTRA consensus from the International Organization for the Study of Inflammatory Bowel Diseases. The Lancet Gastroenterology and Hepatology, 2022, 7, 254-261.	3.7	18
206	New Drugs on the Horizon for IBD. Digestive Diseases, 2014, 32, 74-81.	0.8	17
207	Endoscopy and central reading in inflammatory bowel disease clinical trials: achievements, challenges and future developments. Gut, 2021, 70, gutjnl-2020-320690.	6.1	17
208	The day after COVID-19 in IBD: how to go back to â€˜normalâ€™. Nature Reviews Gastroenterology and Hepatology, 2020, 17, 441-443.	8.2	17
209	Deep Analysis of the Peripheral Immune System in IBD Reveals New Insight in Disease Subtyping and Response to Monotherapy or Combination Therapy. Cellular and Molecular Gastroenterology and Hepatology, 2021, 12, 599-632.	2.3	17
210	Proactive infliximab optimisation using a pharmacokinetic dashboard versus standard of care in patients with Crohnâ€™s disease: study protocol for a randomised, controlled, multicentre, open-label study (the OPTIMIZE trial). BMJ Open, 2022, 12, e057656.	0.8	17
211	Clinical scenarios in IBD: Optimizing the use of conventional and biologic agents. Inflammatory Bowel Diseases, 2010, 16, S1-S11.	0.9	16
212	The Effects of Ustekinumab on Health-related Quality of Life in Patients With Moderate to Severe Crohnâ€™s Disease. Journal of Crohn's and Colitis, 2018, 12, 883-895.	0.6	16
213	Luminally polarized mural and vascular remodeling in ileal strictures of Crohn's disease. Human Pathology, 2018, 79, 42-49.	1.1	16
214	Long-term Safety of Vedolizumab for the Treatment of Ulcerative Colitis or CrohnÊ¼s Disease. American Journal of Gastroenterology, 2013, 108, S502-S503.	0.2	16
215	Early Symptomatic Improvement After Ustekinumab Therapy in Patients With Ulcerative Colitis: 16-Week Data From the UNIFI Trial. Clinical Gastroenterology and Hepatology, 2022, 20, 2858-2867.e5.	2.4	16
216	Lipid Profiles in Patients With Ulcerative Colitis Receiving Tofacitinibâ€”Implications for Cardiovascular Risk and Patient Management. Inflammatory Bowel Diseases, 2021, 27, 797-808.	0.9	15

#	Article	IF	Citations
217	Factors Associated With Longitudinal Psychological and Physiological Stress in Health Care Workers During the COVID-19 Pandemic: Observational Study Using Apple Watch Data. Journal of Medical Internet Research, 2021, 23, e31295.	2.1	15
218	Vedolizumab in Combination With Corticosteroids for Induction Therapy in Crohnâ€™s Disease: A Post Hoc Analysis of GEMINI 2 and 3. Inflammatory Bowel Diseases, 2019, 25, 1375-1382.	0.9	14
219	Wearable Devices Are Well Accepted by Patients in the Study and Management of Inflammatory Bowel Disease: A Survey Study. Digestive Diseases and Sciences, 2021, 66, 1836-1844.	1.1	14
220	Molecular Characterization of Limited Ulcerative Colitis Reveals Novel Biology and Predictors of Disease Extension. Gastroenterology, 2021, 161, 1953-1968.e15.	0.6	14
221	Novel Non-biologic Targets for Inflammatory Bowel Disease. Current Gastroenterology Reports, 2019, 21, 22.	1.1	13
222	Fulminant Colitis. Journal of Gastrointestinal Surgery, 2008, 12, 2157-2159.	0.9	12
223	Predictors of Clinical and Endoscopic Response with Vedolizumab for the Treatment of Moderately-Severely Active Ulcerative Colitis: Results from the us Victory Consortium. Gastroenterology, 2017, 152, S371.	0.6	12
224	New Therapies for the Treatment of Inflammatory Bowel Disease. Surgical Clinics of North America, 2006, 86, 1045-1064.	0.5	11
225	855 Efficacy and Safety of Tofacitinib for Oral Induction Therapy in Patients With Moderate to Severe Crohn's Disease: Results of a Phase 2B Randomized Placebo-Controlled Trial. Gastroenterology, 2016, 150, S182-S183.	0.6	11
226	Changes in Vedolizumab Utilization Across US Academic Centers and Community Practice Are Associated With Improved Effectiveness and Disease Outcomes. Inflammatory Bowel Diseases, 2019, 25, 1854-1861.	0.9	11
227	Tofacitinib for the Treatment of Ulcerative Colitis: Analysis of Nonmelanoma Skin Cancer Rates From the Ulcerative Colitis Clinical Program. Inflammatory Bowel Diseases, 2022, 28, 234-245.	0.9	11
228	Efficacy of Vedolizumab in Ulcerative Colitis by Prior Treatment Failure in GEMINI I, a Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial. Inflammatory Bowel Diseases, 2012, 18, S1-S2.	0.9	10
229	Bridging the Gap Between Host Immune Response and Intestinal Dysbiosis in Inflammatory Bowel Disease: Does Immunoglobulin A Mark the Spot?. Clinical Gastroenterology and Hepatology, 2015, 13, 842-846.	2.4	10
230	Novel Therapies in Inflammatory Bowel Disease: An Evaluation of the Evidence. American Journal of Gastroenterology Supplements (Print), 2016, 3, 38-44.	0.7	10
231	Risk factors for radiation exposure in newly diagnosed IBD patients. Abdominal Radiology, 2016, 41, 1363-1369.	1.0	10
232	Exposure to Biologic Therapy and Childhood Development among Offspring of Women with Inflammatory Bowel Disease: Results from the Piano Registry. Gastroenterology, 2017, 152, S85-S86.	0.6	10
233	When Do You Start and When Do You Stop Screening for Colon Cancer in Inflammatory Bowel Disease?. Clinical Gastroenterology and Hepatology, 2018, 16, 621-623.	2.4	10
234	14 POST-HOC ANALYSIS OF TOFACITINIB CROHNâ€™S DISEASE PHASE 2 INDUCTION EFFICACY IN SUBGROUPS WITH BASELINE ENDOSCOPIC OR BIOMARKER EVIDENCE OF INFLAMMATION. Gastroenterology, 2018, 154, S81.	0.6	10

#	Article	IF	Citations
235	Microscopic heterogeneity in ulcerative colitis: implications for microscopic measurement of disease activity. Gut, 2020, 69, 401-402.	6.1	10
236	Personalised Medicine with IL-23 Blockers: Myth or Reality?. Journal of Crohn's and Colitis, 2022, 16, ii73-ii94.	0.6	10
237	Epidemiology of inflammatory bowel disease and overview of pathogenesis. Medicine and Health, Rhode Island, 2009, 92, 73-7.	0.1	10
238	Testing for Clostridium difficile in Patients Newly Diagnosed with Inflammatory Bowel Disease in a Community Setting. Inflammatory Bowel Diseases, 2015, 21, 564-569.	0.9	9
239	Genetics, Genetic Testing, and Biomarkers of Digestive Diseases. Gastroenterology, 2015, 149, 1131-1133.	0.6	9
240	Tu2006 Ustekinumab Improves General Health Status and Disease-Specific Health Related Quality of Life of Patients with Moderate to Severe Crohn's Disease: Results from the UNITI and IMUNITI Phase 3 Clinical Trials. Gastroenterology, 2016, 150, S1004.	0.6	9
241	Maintenance of Quality of Life Improvement in a Phase 3 Study of Tofacitinib for Patients with Moderately to Severely Active Ulcerative Colitis. Gastroenterology, 2017, 152, S601-S602.	0.6	9
242	Ileocolic anastomotic inflammation after resection for Crohnâ€™s disease indicates disease recurrence: a histopathologic study. Scandinavian Journal of Gastroenterology, 2020, 55, 795-799.	0.6	9
243	OSCCAR: Ocean State Crohn's and Colitis Area Registry. Medicine and Health, Rhode Island, 2009, 92, 82-5, 88.	0.1	9
244	IOIBD Recommendations for Clinical Trials in Ulcerative Proctitis: The PROCTRIAL Consensus. Clinical Gastroenterology and Hepatology, 2022, 20, 2619-2627.e1.	2.4	9
245	Optimal Crohn's disease activity index (CDAI) response criteria is defined by decreaseÈ¦100 points. Gastroenterology, 2003, 124, A206.	0.6	8
246	Within You, Without You: Is Gastroenterology Ready to Embrace the â€œExposomeâ€?. Gastroenterology, 2012, 142, 1403-1404.	0.6	8
247	Corticosteroid Use in a Prospective, Community-Based Cohort of Newly Diagnosed Inflammatory Bowel Disease Patients. Digestive Diseases and Sciences, 2016, 61, 1635-1640.	1.1	8
248	Efficient augmentation and relaxation learning for individualized treatment rules using observational data. Journal of Machine Learning Research, 2019, 20, .	62.4	8
249	Vedolizumab Maintenance Therapy for Ulcerative Colitis: Results of GEMINI I, a Randomized, Placebo-Controlled, Double-Blind, Multicenter Phase 3 Trial. American Journal of Gastroenterology, 2012, 107, S609-S610.	0.2	7
250	Long-Term Effectiveness and Safety of Vedolizumab in Patients with Ulcerative Colitis: 5-Year Cumulative Exposure of Gemini 1 Completers Rolling into the Gemini Open-Label Extension Study. Gastroenterology, 2017, 152, S602.	0.6	7
251	Dietary behaviors in newly diagnosed youth with inflammatory bowel disease. Children's Health Care, 2017, 46, 408-420.	0.5	7
252	The Impact of Raising the Bar for Clinical Trials in Ulcerative Colitis. Journal of Crohn's and Colitis, 2019, 13, 1217-1226.	0.6	7

#	Article	IF	Citations
253	Improved Smoking Cessation Rates in a Pharmacist-Led Program Embedded in an Inflammatory Bowel Disease Specialty Medical Home. Journal of Pharmacy Practice, 2022, 35, 827-835.	0.5	7
254	Treatment of ulcerative colitis. Current Opinion in Gastroenterology, 1999, 15, 298.	1.0	7
255	CROHN'S DISEASE AND IL-10 THERAPY: PROMISE REGAINED?. Inflammatory Bowel Diseases, 2003, 9, 210-211.	0.9	6
256	Practices, attitudes, and knowledge about Crohnâ€™s disease and smoking cessation among gastroenterologists. European Journal of Gastroenterology and Hepatology, 2018, 30, 155-160.	0.8	6
257	Current Trends in IBDâ€”Development of Mucosal-Based Biomarkers and a Novel Minimally Invasive Recoverable Sampling System. Inflammatory Bowel Diseases, 2021, 27, S17-S24.	0.9	6
258	Babesiosis in a Patient on Infliximab for CrohnÊ¼s Disease. Inflammatory Bowel Diseases, 2010, 16, 1269-1270.	0.9	5
259	Reductions in Corticosteroid Use in Patients with Ulcerative Colitis or CrohnÊ¼s Disease Treated with Vedolizumab. American Journal of Gastroenterology, 2013, 108, S503.	0.2	5
260	Effects of Increased Vedolizumab Dosing Frequency on Disease Activity in Ulcerative Colitis and Crohnâ€™s Disease. American Journal of Gastroenterology, 2014, 109, S478-S479.	0.2	5
261	S0703â€ƒTofacitinib for the Treatment of Ulcerative Colitis: Up to 6.8 Years of Safety Data From Global Clinical Trials. American Journal of Gastroenterology, 2020, 115, S353-S354.	0.2	5
262	Persistence of treatment in patients with ulcerative colitis who responded to tofacitinib therapy: Data from the openâ€label, longâ€term extension study, <scp>OCTAVE</scp> open. Alimentary Pharmacology and Therapeutics, 2022, , .	1.9	5
263	Case 36-1997. New England Journal of Medicine, 1997, 337, 1532-1540.	13.9	4
264	Sustained Corticosteroid-Free Clinical Remission During Vedolizumab Maintenance Therapy in Patients with Ulcerative Colitis on Stable Concomitant Corticosteroids During Induction Therapy: A Post Hoc Analysis of GEMINI 1 . Clinical and Experimental Gastroenterology, 2020, Volume 13, 211-220.	1.0	4
265	Tofacitinib for Maintenance Therapy in Patients With Active Ulcerative Colitis in the Phase 3 OCTAVE Sustain Trial: Results by Local and Central Endoscopic Assessments. American Journal of Gastroenterology, 2017, 112, S329-S330.	0.2	4
266	Agreement between local and central reading of endoscopic disease activity in ulcerative colitis: results from the tofacitinib OCTAVE trials. Alimentary Pharmacology and Therapeutics, 2021, 54, 1442-1453.	1.9	4
267	IRRITABLE-INFLAMMATORY BOWEL DISEASE: RECOGNIZING A NEW OVERLAP SYNDROME AND AN ENIGMA WRAPPED INSIDE A PUZZLE. Inflammatory Bowel Diseases, 2002, 8, 373-374.	0.9	3
268	Variation in Severity Assessment and Initial Mesalamine Dose Selection for Ulcerative Colitis in Community Practice. Journal of Clinical Gastroenterology, 2006, 40, 587-591.	1.1	3
269	Vedolizumab Induction Therapy for Patients With Crohnâ€™s Disease and Prior Anti-TNF Antagonist Failure: A Randomized, Placebo-controlled, Double-blind, Multicenter Trial. Inflammatory Bowel Diseases, 2012, 18, S24-S25.	0.9	3
270	Sustained Therapeutic Benefit of Vedolizumab Throughout 1 Year in Ulcerative Colitis in GEMINI I, a Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial. Inflammatory Bowel Diseases, 2012, 18, S25.	0.9	3

#	Article	IF	Citations
271	Comment on â€˜Anti-Adhesion Therapies and the Rule of 3 for Rare Eventsâ€™. American Journal of Gastroenterology, 2014, 109, 1083-1084.	0.2	3
272	Efficacy and Safety of Oral Tofacitinib as Maintenance Therapy in Patients with Moderate to Severe Ulcerative Colitis: Results from a Phase 3 Randomized Controlled Trial. Gastroenterology, 2017, 152, S199.	0.6	3
273	Impact of Real World Home-Based Remote Monitoring on Quality of Care and Quality of Life in IBD Patients: Interim Results of Pragmatic Randomized Trial. Gastroenterology, 2017, 152, S600-S601.	0.6	3
274	What Is the Role of the Inflammatory Bowel Disease Panel in Diagnosis and Treatment?. Clinical Gastroenterology and Hepatology, 2018, 16, 618-620.	2.4	3
275	Methodology and Initial Results From a Real-World Observational Cohort of Patients With Inflammatory Bowel Disease: TARGET-IBD. Crohn's & Colitis 360, 2021, 3, .	0.5	3
276	Tofacitinib Has Induction Efficacy in Moderately to Severely Active Ulcerative Colitis, Regardless of Prior TNF Inhibitor Therapy. American Journal of Gastroenterology, 2016, 111, S261.	0.2	3
277	Achieving Synergy: Linking an Internet-Based Inflammatory Bowel Disease Cohort to a Community-Based Inception Cohort and Multicentered Cohort in Inflammatory Bowel Disease. Journal of Medical Internet Research, 2016, 18, e124.	2.1	3
278	Evaluation of possible inflammatory bowel disease: a survey of Rhode Island physicians. Medicine and Health, Rhode Island, 2012, 95, 4-8.	0.1	3
279	Objective disease activity assessment and therapeutic drug monitoring prior to biologic therapy changes in routine inflammatory bowel disease clinical practice: TARGET-IBD. BMC Gastroenterology, 2022, 22, 71.	0.8	3
280	Toward new questions in inflammatory bowel disease in 1995. Current Opinion in Gastroenterology, 1996, 12, 319-321.	1.0	2
281	Funding and Grantsmanship. Inflammatory Bowel Diseases, 2005, 11, S34-S37.	0.9	2
282	389 A Randomized, Double-Blind, Placebo-Controlled Trial of Basiliximab with Concomitant Corticosteroids in Steroid-Refractory Ulcerative Colitis. Gastroenterology, 2009, 136, A-65.	0.6	2
283	The Incidence of Influenza and Influenza-related Complications in Inflammatory Bowel Disease Patients across the United States. American Journal of Gastroenterology, 2013, 108, S554.	0.2	2
284	Mark Warren Babyatsky, MD (June 29, 1959â€“August 25, 2014). Gastroenterology, 2014, 147, 1189-1190.	0.6	2
285	Tu1908 Safety of Vedolizumab in Inflammatory Bowel Disease in a Multi-Center Real World Consortium. Gastroenterology, 2016, 150, S974.	0.6	2
286	Sa1888 Efficacy and Predictors of Outcomes of Vedolizumab for Ulcerative Colitis in Clinical Practice. Gastroenterology, 2016, 150, S392-S393.	0.6	2
287	Long-Term Efficacy and Safety of Ustekinumab for Crohnâ€™s Disease: Results From Im-Uniti Long-Term Extension Through two Years. Gastroenterology, 2017, 152, S585.	0.6	2
288	The Whys and Hows of Fourth-Year Inflammatory Bowel Disease Fellowships. Digestive Diseases and Sciences, 2017, 62, 1116-1118.	1.1	2

#	Article	IF	Citations
289	Rates and Predictors of Surgery in Inflammatory Bowel Disease Patients Initiating Vedolizumab Therapy: Results from the Victory Consortium. Gastroenterology, 2017, 152, S779.	0.6	2
290	Letter: corticosteroid use alongside tofacitinib in OCTAVE Open. Authors' reply. Alimentary Pharmacology and Therapeutics, 2020, 51, 997-998.	1.9	2
291	Older Adult Patients Use More Aminosalicylate Monotherapy Compared With Younger Patients With Inflammatory Bowel Disease. Journal of Clinical Gastroenterology, 2021, Publish Ahead of Print, .	1.1	2
292	PILOT STUDY ON THE SAFETY AND EFFICACY OF GRANULOCYTE/MONOCYTE ADSORPTION APHERESIS WITH ADACOLUMN IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE. American Journal of Gastroenterology, 2004, 99, S263-S264.	0.2	2
293	Vedolizumab for Moderate to Severely Active Inflammatory Bowel Disease: A Multicenter U.S. Consortium. American Journal of Gastroenterology, 2015, 110, S809.	0.2	2
294	Tofacitinib for Induction Therapy in Patients with Active Ulcerative Colitis in Two Phase 3 Clinical Trials: Results by Local and Central Endoscopic Assessments. American Journal of Gastroenterology, 2016, 111, S319-S320.	0.2	2
295	S777â€ƒTofacitinib for the Treatment of Ulcerative Colitis: Up to 7.8 Years of Safety Data from Global Clinical Trials. American Journal of Gastroenterology, 2021, 116, S360-S360.	0.2	2
296	P031â€ƒImpact of Prior Biologic Exposure on Response to Ozanimod for Moderate-to-Severe Ulcerative Colitis in the Phase 3 True North Study. American Journal of Gastroenterology, 2021, 116, S8-S8.	0.2	2
297	Biologic Agents: Data in Adults and Children. Inflammatory Bowel Diseases, 1998, 4, 125-127.	0.9	1
298	New biologic agents: A critical appraisal. Current Gastroenterology Reports, 1999, 1, 470-475.	1.1	1
299	Infliximab does not result in increased, abscess development in fistulizing Crohn's disease: Results from ACCENT II. Gastroenterology, 2003, 124, A379.	0.6	1
300	Infliximab vs. Adalimumab for Crohn's disease: authors' reply. Alimentary Pharmacology and Therapeutics, 2008, 28, 1266-1267.	1.9	1
301	Response to Letter by Field et al, â€œInfluenza Vaccinations: Should They Really be Encouraged for IBD Patients Being Treated with Immunosuppressives?â€• Inflammatory Bowel Diseases, 2009, 15, 651-652.	0.9	1
302	Transition to Adult Care. Pediatric and Adolescent Medicine, 2009, , 191-198.	0.4	1
303	LRRK2 is an Interferon-gamma Target Involved in Immune Responses. Clinical Immunology, 2010, 135, S56.	1.4	1
304	Lloyd F. Mayer, MD, June 21, 1952 â€“ September 5, 2013. Gastroenterology, 2013, 145, 1169-1170.	0.6	1
305	Tu1994 Documentation of IBD Quality of Care and Psychosocial Metrics Among Patients With IBD: Baseline Analysis of Ongoing Pragmatic Randomized Controlled Trial. Gastroenterology, 2016, 150, S1000.	0.6	1
306	Sa1889 Efficacy and Predictors of Outcomes of Vedolizumab for Crohn's Disease in Clinical Practice. Gastroenterology, 2016, 150, S393.	0.6	1

#	Article	IF	Citations
307	Mo1908 Colectomy Free Survival is Independent of Initial Infliximab Dosing Strategy in Hospitalized Ulcerative Colitis Patients. Gastroenterology, 2016, 150, S813.	0.6	1
308	Opportunistic Screening for Bone Disease Using Abdominal CT Scans Obtained for other Reasons in Newly Diagnosed IBD Patients. Gastroenterology, 2017, 152, S607-S608.	0.6	1
309	Defining Patient-Centered Outcomes for IBD and an International, Cross-Disciplinary Consensus. Gastroenterology, 2017, 152, S137-S138.	0.6	1
310	Correlation of Clinical and Endoscopic Outcomes in Patients with Active Crohnâ€™s Disease Treated with Mongersen (GED-0301). Gastroenterology, 2017, 152, S198.	0.6	1
311	There is no Difference in Short-Term Colectomy Rate between Infliximab-Exposed and Infliximab-NaÃ¯ve Hospitalized Ulcerative Colitis Patients. Gastroenterology, 2017, 152, S396.	0.6	1
312	Women's Preferences for IBD Medical Therapy during Pregnancy. Gastroenterology, 2017, 152, S84-S85.	0.6	1
313	P057 IMPROVED QUALITY OF CARE AND QUALITY OF LIFE FOR IBD PATIENTS USING MOBILE BASED REMOTE MONITORING PLATFORM: A RANDOMIZED CONTROL TRIAL. Gastroenterology, 2018, 154, S30.	0.6	1
314	Letter: thromboembolic and cardiovascular events with tofacitinib in ulcerative colitisâ€”two cases in real world clinical practice. Authorsâ€™ reply. Alimentary Pharmacology and Therapeutics, 2020, 51, 1209-1210.	1.9	1
315	Mucosal Healing in Patients with Ulcerative Colitis Associates with a Reduced Colectomy Risk, High Incidence of Symptomatic Remission, and Corticosteroid-Free State. American Journal of Gastroenterology, 2010, 105, S438-S439.	0.2	1
316	Ocean State CrohnÊ¼s and Colitis Area Registry (OSCCAR): Incidence of CrohnÊ¼s Disease and Ulcerative Colitis in a Prospective, Population-Based Inception Cohort in Rhode Island. American Journal of Gastroenterology, 2010, 105, S425-S426.	0.2	1
317	Integrated Safety Analyses of Tofacitinib in Ulcerative Colitis Clinical Trials. American Journal of Gastroenterology, 2017, 112, S403-S404.	0.2	1
318	Impact of Automated Digital Navigation Program on Bowel Preparation Quality and Patient Satisfaction for Colonoscopy: A Comparative Study Across Multiple Sites. Iproceedings, 2019, 5, e15270.	0.1	1
319	671â€ƒAn Update on the Analysis of Non-Melanoma Skin Cancer in the Tofacitinib Ulcerative Colitis Program. American Journal of Gastroenterology, 2019, 114, S395-S395.	0.2	1
320	Clinical features of inflammatory bowel disease. Current Opinion in Gastroenterology, 1998, 14, 300-305.	1.0	0
321	Risk of early surgery in Crohn's disease: Implications for early treatment strategies. Gastroenterology, 2001, 120, A449-A450.	0.6	0
322	COLLAGENOUS COLITIS: BUDESONIDE PASSES THE PLACEBO TEST. Inflammatory Bowel Diseases, 2002, 8, 308.	0.9	0
323	MAKING SENSE OF ANTISENSE THERAPY FOR MURINE INFLAMMATORY BOWEL DISEASE. Inflammatory Bowel Diseases, 2002, 8, 309-310.	0.9	0
324	THE SORCERER'S APPRENTICE. Inflammatory Bowel Diseases, 2002, 8, 310.	0.9	0

#	Article	IF	Citations
325	PERHAPS WE CAN, BUT SHOULD WE?. , 2002, 8, 372-373.		0
326	O BROTHER, WHERE ART THOU? THE CASE FOR SIBLINGS, ENVIRONMENT, AND INFLAMMATORY BOWEL DISEASE. Inflammatory Bowel Diseases, 2003, 9, 211-212.	0.9	0
327	A CROHN'S REPERTOIRE: T CELL RECEPTOR Î³Î´. Inflammatory Bowel Diseases, 2003, 9, 213-214.	0.9	0
328	Long-term treatment of rectovaginal fistulas in Crohn's disease: Response to infliximab in the ACCENT II trial. Gastroenterology, 2003, 124, A380.	0.6	0
329	Infliximab, Adalimumab and Certolizumab. Inflammatory Bowel Diseases, 2006, 12, S6-S7.	0.9	0
330	GM-CSF. Inflammatory Bowel Diseases, 2006, 12, S12.	0.9	0
331	PR3 PATIENTS', PARENTS', AND PHYSICIANS' RISK-BENEFIT TRADE-OFF PREFERENCES FOR CROHN'S DISEASE TREATMENTS. Value in Health, 2007, 10, A225-A226.	0.1	0
332	Crohnâ€™s Disease: Advise and Consent. Canadian Journal of Gastroenterology & Hepatology, 2007, 21, 791-793.	1.8	0
333	The Utility of Genetics in Classifying Ulcerative Colitis and Crohn's Disease Patients. Gastroenterology, 2011, 140, S-268.	0.6	0
334	Nutrition and dietary behaviors in pediatric Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2011, 17, S32.	0.9	0
335	Low Rate of Clostridium Difficile Infection Testing in Patients With Newly Diagnosed Inflammatory Bowel Disease and Diarrhea. Inflammatory Bowel Diseases, 2012, 18, S42-S43.	0.9	0
336	Tu1238 Body Image Dissatisfaction in an Incident Cohort of Inflammatory Bowel Disease: A Study From the Ocean State Crohn's and Colitis Area Registry. Gastroenterology, 2012, 142, S-781-S-782.	0.6	0
337	Mo1263 Male Sexual Function in an Incident Cohort of Inflammatory Bowel Disease: A Longitudnal Study From the Ocean State Crohn's and Colitis Area Registry. Gastroenterology, 2013, 144, S-621-S-622.	0.6	0
338	Vedolizumab Induces Clinical Response and Remission Across a Range of Baseline Fecal Calprotectin Levels in Patients with Ulcerative Colitis: Results from GEMINI 1. American Journal of Gastroenterology, 2014, 109, S486.	0.2	0
339	Diseases of the Anus and Rectum. , 2014, , 477-486.		0
340	P-017â€ƒYlâ€ƒMucosal Healing Is Associated with Improved Long-Term Outcomes in Ulcerative Colitis. Inflammatory Bowel Diseases, 2016, 22, S14.	0.9	0
341	Reply. Clinical Gastroenterology and Hepatology, 2016, 14, 1361-1362.	2.4	0
342	Letter: mucosal healing is associated with improved longâ€term outcomes in Crohn's disease â€“ authors' reply. Alimentary Pharmacology and Therapeutics, 2016, 43, 1347-1348.	1.9	0

#	Article	IF	Citations
343	Tu1962 Looking Beyond Symptoms and Disease Activity to Define Disease Severity in Inflammatory Bowel Disease: Results of an IOIBD Specialist Panel. Gastroenterology, 2016, 150, S991.	0.6	0
344	P-016â€ƒYlâ€ƒMucosal Healing Is Associated with Improved Long-Term Outcomes in CrohnÊ¼s Disease. Inflammatory Bowel Diseases, 2016, 22, S14.	0.9	0
345	P-063â€ƒPsychosocial Burden Among Patients with IBD. Inflammatory Bowel Diseases, 2016, 22, S29.	0.9	0
346	Optimal Management of Fistulizing Crohnâ€™s Disease. , 2017, , 381-386.		0
347	Reply to Letter to the Editor of Dr. Lai and Colleagues. Inflammatory Bowel Diseases, 2019, 25, e166-e166.	0.9	0
348	757â€ƒHistologic Improvement With Vedolizumab vs. Adalimumab in Ulcerative Colitis: Results From VARSITY. American Journal of Gastroenterology, 2019, 114, S442-S442.	0.2	0
349	716â€ƒEarly Clinical Response and Remission With Vedolizumab Versus Adalimumab in Ulcerative Colitis: Results From VARSITY. American Journal of Gastroenterology, 2019, 114, S421-S421.	0.2	0
350	Response to Ribaldone. American Journal of Gastroenterology, 2019, 114, 826-827.	0.2	0
351	Response to Chapman and Jones. American Journal of Gastroenterology, 2019, 114, 828-828.	0.2	0
352	644â€ƒIncidence of Venous Thromboembolic Events in Patients With Ulcerative Colitis Treated With Tofacitinib in the Ulcerative Colitis Clinical Development Program. American Journal of Gastroenterology, 2019, 114, S377-S377.	0.2	0
353	The Risk of Developing CrohnÊ¼s Disease after an Appendectomy. American Journal of Gastroenterology, 2006, 101, S423-S424.	0.2	0
354	TOUCHâ„¢ Study Patient Outcomes: The Impact of Natalizumab on Common Measures of Quality of Life in CD patients. American Journal of Gastroenterology, 2009, 104, S418.	0.2	0
355	TOUCHâ„¢ Study Patient Outcomes: The Impact of Natalizumab on CrohnÊ¼s Disease Severity. American Journal of Gastroenterology, 2009, 104, S420.	0.2	0
356	TOUCHâ„¢ Study Patient Outcomes: The Impact of Natalizumab on Utilization of Healthcare Resources by the Patients and Their Associated Treatment Satisfaction. American Journal of Gastroenterology, 2009, 104, S416.	0.2	0
357	TOUCHâ„¢ Study Patient Outcomes: Workforce Participation, Productivity and the Impact of Natalizumab. American Journal of Gastroenterology, 2009, 104, S417-S418.	0.2	0
358	A Decision Analysis to Define the Thresholds at Which the Risks of Combination Infliximab and Azathioprine Therapy Outweigh Its Benefits. American Journal of Gastroenterology, 2009, 104, S469-S470.	0.2	0
359	Medical Therapy of IBD in the First Year After Diagnosis: Preliminary Results from the Ocean State CrohnÊ¼s and Colitis Area Registry (OSCCAR). American Journal of Gastroenterology, 2010, 105, S427.	0.2	0
360	IBD: Medical Management. , 2011, , 463-478.		0

#	Article	IF	Citations
361	Sensitivity, Specificity, and Stability of Seromarkers in a Prospective, Population-based Inception Cohort of Newly-diagnosed Inflammatory Bowel Disease (IBD). American Journal of Gastroenterology, 2013, 108, S504-S505.	0.2	0
362	Radiation Exposure to the Abdomen and Pelvis in Patients Newly Diagnosed with Inflammatory Bowel Disease. American Journal of Gastroenterology, 2013, 108, S518.	0.2	0
363	A Pilot Study on the Effects of Smoking Cessation on Intestinal Gene Expression and the Microbiome. American Journal of Gastroenterology, 2016, 111, S326-S327.	0.2	0
364	Real World Usage Patterns of Vedolizumab in Inflammatory Bowel Disease: Results From the VICTORY Consortium: 2017 Presidential Poster Award. American Journal of Gastroenterology, 2017, 112, S400-S401.	0.2	0
365	Safety of Ustekinumab With and Without Concomitant Corticosteroids or Immunosuppressants in Patients With Moderately to Severely Active CrohnÊ¼s Disease. American Journal of Gastroenterology, 2017, 112, S329-S330.	0.2	0
366	Response to Chamberlin and Borody. American Journal of Gastroenterology, 2019, 114, 171-174.	0.2	0
367	Womenâ€™s Willingness to Accept Risks of Medication for Inflammatory Bowel Disease During Pregnancy. Patient, 2021, , .	1.1	0
368	S0664â€ƒDisease Control and Changes in Individual Treatment Outcomes From Week 14 to Week 52 With Vedolizumab or Adalimumab in Ulcerative Colitis: A VARSITY Trial Post Hoc Analysis. American Journal of Gastroenterology, 2020, 115, S332-S333.	0.2	0
369	S0887â€ƒFecal Calprotectin as a Surrogate Marker of Clinical Remission, Clinical Response, Endoscopic Improvement, and Histo-Endoscopic Mucosal Healing: UNIFI Induction Study. American Journal of Gastroenterology, 2020, 115, S457-S458.	0.2	0
370	Comparative Effectiveness Research in Inflammatory Bowel Disease: The VARSITY Study and Beyond. Gastroenterology and Hepatology, 2019, 15, 682-684.	0.2	0